Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edaravone - Mitsubishi Tanabe Pharma

Next Previous
X
Search
Drug Profile

Edaravone - Mitsubishi Tanabe Pharma

Alternative Names: 1-phenyl-3-methyl-5-pyrazolone; Edarabone; MCI-186; MT 1186; Norphenazone; Phenylmethylpyrazolone; RADICAVA; Radicava; RADICAVA ORS; RADICUT; Radicut; Radicut Bag

Latest Information Update: 20 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Mitsubishi Pharma Corporation; Mitsubishi Tanabe Pharma America; Mitsubishi Tanabe Pharma Canada; Mitsubishi Tanabe Pharma Corporation
  • Class Anti-ischaemics; Antidementias; Antihaemorrhagics; Antiparkinsonians; Hepatoprotectants; Neuroprotectants; Pyrazolones; Small molecules; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Amyotrophic lateral sclerosis; Cerebral infarction
  • Phase II Stroke
  • No development reported Liver disorders
  • Discontinued Myocardial ischaemia; Parkinson's disease; Reperfusion injury; Subarachnoid haemorrhage

Most Recent Events

  • 17 Jun 2024 Launched for Amyotrophic lateral sclerosis in Puerto Rico (IV) before June 2024
  • 17 Jun 2024 Launched for Amyotrophic lateral sclerosis in Puerto Rico (PO) before June 2024
  • 17 Jun 2024 Adverse events data from the phase III MT-1186-A03 trial in Amyotrophic lateral sclerosis released by Mitsubishi Tanabe Pharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top